Australian Longitudinal Study on Women's Health
Search Icon Created with Sketch.
Icons / Login Created with Sketch.
Icons / User Created with Sketch.
Search Icon Created with Sketch.

Proton pump inhibitor use and subsequent prescribing of anti-osteoporosis medication

Approved: 2014

Collaborators:

  • Dr Geeske Peeters
  • Prof Annette Dobson
  • Prof Susan Tett
  • Ms Marielle Van der Hoorn
  • Dr Oscar de Vries

Synopsis

Proton pump inhibitors (PPIs) are commonly used in Australia to prevent and treat a range of gastrointestinal disorders, including peptic ulcer and gastro-oesophageal reflux. Use of PPIs, especially at higher doses or for long periods of time has been reported to lead to increased risk of osteoporosis and bone fractures. We plan to investigate whether women in the older age cohort of ALSWH receiving PPIs have a higher rate of subsequent prescribing of anti-osteoporosis medications. Australia has a higher use of PPIs than other countries, therefore evidence of increased osteoporosis possibly attributed to this would be of concern and could lead to reappraisal of the risk/benefit analysis for clinical use of PPIs.